Strongbridge Biopharma plc (NASDAQ:SBBP) has received an average recommendation of “Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $13.50.

Several equities analysts have issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Strongbridge Biopharma in a research note on Tuesday. They issued an “overweight” rating and a $14.00 price objective for the company. Zacks Investment Research cut shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Oppenheimer started coverage on shares of Strongbridge Biopharma in a report on Thursday, August 10th. They issued an “outperform” rating and a $12.00 target price for the company. ValuEngine cut shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Strongbridge Biopharma in a report on Wednesday, November 15th.

Strongbridge Biopharma (SBBP) traded down $0.45 during midday trading on Tuesday, reaching $6.30. 156,300 shares of the company’s stock traded hands, compared to its average volume of 108,647. The company has a debt-to-equity ratio of -1.89, a current ratio of 4.70 and a quick ratio of 4.61. Strongbridge Biopharma has a one year low of $2.00 and a one year high of $8.85.

A number of institutional investors have recently modified their holdings of SBBP. State of Wisconsin Investment Board acquired a new stake in shares of Strongbridge Biopharma in the second quarter valued at approximately $114,000. Rhumbline Advisers acquired a new stake in shares of Strongbridge Biopharma in the second quarter valued at approximately $154,000. California State Teachers Retirement System acquired a new stake in shares of Strongbridge Biopharma in the second quarter valued at approximately $277,000. Teachers Advisors LLC acquired a new stake in shares of Strongbridge Biopharma in the second quarter valued at approximately $297,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Strongbridge Biopharma in the second quarter valued at approximately $331,000. 57.53% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/05/strongbridge-biopharma-plc-sbbp-given-consensus-rating-of-buy-by-brokerages.html.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Ratings for Strongbridge Biopharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma plc and related companies with MarketBeat.com's FREE daily email newsletter.